Healthcare Global Enterprises Ltd Stock Price Today (NSE: HCG)
Fundamental Score
Healthcare Global Enterprises Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Healthcare Global Enterprises Ltd share price today is ₹631.65, down 2.24% on NSE/BSE as of 2 June 2026. Healthcare Global Enterprises Ltd (HCG) is a Mid-cap company in the Hospital sector with a market capitalisation of ₹10.47K (Cr). The 52-week high for HCG share price is ₹804.65 and the 52-week low is ₹513.30. At a P/E ratio of 296.22x, HCG is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 5.14% and a debt-to-equity ratio of 1.92.
Healthcare Global Enterprises Ltd Share Price Chart — NSE/BSE Historical Performance
Healthcare Global Enterprises Ltd share price chart: 14.29% return over the past month. 52-week high ₹804.65, 52-week low ₹513.30.
Healthcare Global Enterprises Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹663.00 | ₹664.00 | ₹651.80 | ₹659.95 | 90.20K (Cr) | |
| ₹648.35 | ₹658.95 | ₹648.35 | ₹656.00 | 2.05L (Cr) | |
| ₹654.05 | ₹663.75 | ₹645.00 | ₹655.95 | 3.22L (Cr) | |
| ₹627.95 | ₹661.00 | ₹627.95 | ₹654.30 | 4.00L (Cr) | |
| ₹652.05 | ₹655.00 | ₹614.15 | ₹627.00 | 7.31L (Cr) | |
| ₹632.00 | ₹659.25 | ₹632.00 | ₹652.05 | 2.38L (Cr) | |
| ₹637.95 | ₹653.70 | ₹632.00 | ₹646.85 | 1.32L (Cr) | |
| ₹641.50 | ₹646.00 | ₹620.05 | ₹632.25 | 2.25L (Cr) | |
| ₹615.05 | ₹662.15 | ₹615.05 | ₹637.20 | 5.72L (Cr) | |
| ₹614.95 | ₹620.80 | ₹607.20 | ₹617.00 | 86.32K (Cr) |
Healthcare Global Enterprises Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹579.80 | ₹664.00 | ₹575.60 | ₹659.95 | +13.82% | |
| ₹536.00 | ₹584.85 | ₹516.85 | ₹572.55 | +6.82% | |
| ₹563.00 | ₹587.15 | ₹513.30 | ₹525.20 | -6.71% | |
| ₹591.10 | ₹613.95 | ₹556.50 | ₹572.11 | -3.21% | |
| ₹667.80 | ₹675.00 | ₹567.25 | ₹592.05 | -11.34% | |
| ₹724.25 | ₹745.00 | ₹657.05 | ₹662.00 | -8.60% | |
| ₹747.00 | ₹770.90 | ₹696.95 | ₹730.35 | -2.23% | |
| ₹640.35 | ₹804.65 | ₹630.60 | ₹747.15 | +16.68% | |
| ₹673.75 | ₹708.00 | ₹613.75 | ₹643.30 | -4.52% | |
| ₹622.05 | ₹701.10 | ₹583.05 | ₹673.75 | +8.31% | |
| ₹550.60 | ₹626.45 | ₹531.35 | ₹622.05 | +12.98% | |
| ₹556.95 | ₹560.90 | ₹520.10 | ₹550.60 | -1.14% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Overvalued cancer play with stretched financials and integration risk; KKR is the only safety net.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Healthcare Global Enterprises (HCG) completed a rights issue of equity shares aggregating to The equity shares commenced trading on BSE and NSE on April 1, 2026. HCG also received a three-week extension for the Vizag Hospital stake acquisition.
CORE STORY (THE REAL GAME)
HCG is a bet on the growing demand for cancer care in India, fueled by rising incidence and under-penetration of quality treatment. KKR's acquisition of a controlling stake signals confidence in this long-term trend.
- Rights issue completed, reducing immediate funding pressure
- Vizag Hospital acquisition on track
- KKR ownership provides stability
- Faster-than-expected integration of Vizag Hospital
- Significant improvement in interest coverage ratio
- New partnerships with international healthcare providers
- High Debt/Equity ratio of 1.92x
- Extremely high P/E of 296.22x vs industry average of 52.84x
- Micro/Small Cap - liquidity risk
FII increased stake by 1.43%, DII increased stake by 5.14%, Promoter increased stake by 1.32%.
Healthcare spending in India is increasing, but rupee depreciation could impact costs.
Acquiring additional 34% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 1.6 billion.
Yes - Free Cash Flow 5Y: ₹571.13 Cr
HCG needs to demonstrate improved profitability and efficient integration of Vizag Hospital in the next 6 months. Failure to do so will expose the stretched valuation.
Primary Thesis Risk
Inability to service debt due to poor profitability will trigger a collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Healthcare Global Enterprises Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Healthcare Global Enterprises Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HCG across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (16.59%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (16.86%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.22% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (17.79% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.34% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹571.13 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
6 factors identified
Below-Average Return on Equity (5.14%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.56%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 296.22x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Elevated Debt Levels (D/E: 1.92)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.24x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Healthcare Global Enterprises Ltd vs Hospital Peers
Peer Comparison - Hospital
Compare Healthcare Global Enterprises Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
36.4/100 | ₹631.65₹632 | ₹10474.40₹10474.40 | 296.22Average 296.2 Average | 5.14%Poor 5.14% Poor | 8.56%Poor 8.56% Poor | 1.92Average 1.9 Average | 19.34%Excellent 19.34% Excellent | 15.22%Excellent 15.22% Excellent | 0.00% | |
Max Healthcare Institute LtdMax Healthcare ... MAXHEALTH • 543220 | 69.1/100 | ₹993.45₹993 | ₹109416.28₹109416.28 | 77.65Average 77.7 Average | 12.72%Average 12.72% Average | 14.88%Average 14.88% Average | 0.33Excellent 0.3 Excellent | 80.50%Excellent 80.50% Excellent | 46.01%Excellent 46.01% Excellent | 0.13% |
Apollo Hospitals Enterprise LtdApollo Hospital... APOLLOHOSP • 508869 | 50.2/100 | ₹8272.50₹8273 | ₹104825.94₹104825.94 | 62.70Average 62.7 Average | 18.42%Good 18.42% Good | 16.64%Good 16.64% Good | 0.88Good 0.9 Good | 33.72%Excellent 33.72% Excellent | 14.15%Good 14.15% Good | 0.26% |
Fortis Healthcare LtdFortis Healthca... FORTIS • 532843 | 55.6/100 | ₹960.90₹961 | ₹68301.24₹68301.24 | 67.80Average 67.8 Average | 10.13%Average 10.13% Average | 11.96%Average 11.96% Average | 0.34Excellent 0.3 Excellent | 70.31%Excellent 70.31% Excellent | 10.93%Good 10.93% Good | 0.11% |
Narayana Hrudayalaya LtdNarayana Hruday... NH • 539551 | 62.2/100 | ₹1920.20₹1920 | ₹39051.19₹39051.19 | 45.92Average 45.9 Average | 24.22%Excellent 24.22% Excellent | 20.75%Excellent 20.75% Excellent | 0.58Good 0.6 Good | 43.49%Excellent 43.49% Excellent | 11.88%Good 11.88% Good | 0.24% |
Aster DM Healthcare LtdAster DM Health... ASTERDM • 540975 | 15.4/100 | ₹741.25₹741 | ₹34688.15₹34688.15 | 94.51Average 94.5 Average | 8.26%Poor 8.26% Poor | 10.68%Average 10.68% Average | 0.46Excellent 0.5 Excellent | -7.24%Poor -7.24% Poor | -13.71%Poor -13.71% Poor | 0.75% |
Global Health LtdGlobal Health L... MEDANTA • 543654 | 61/100 | ₹1207.80₹1208 | ₹33498.00₹33498.00 | 56.03Average 56.0 Average | 16.48%Good 16.48% Good | 19.74%Good 19.74% Good | 0.25Excellent 0.3 Excellent | 70.15%Excellent 70.15% Excellent | 19.73%Excellent 19.73% Excellent | 0.04% |
45.1/100 | ₹784.45₹784 | ₹27605.54₹27605.54 | 83.99Average 84.0 Average | 18.48%Good 18.48% Good | 15.00%Good 15.00% Good | 1.40Average 1.4 Average | 25.01%Excellent 25.01% Excellent | 22.01%Excellent 22.01% Excellent | 0.00% | |
Dr Agarwals Health Care LtdDr Agarwals Hea... AGARWALEYE • 544350 | 51.2/100 | ₹479.95₹480 | ₹16844.04₹16844.04 | 145.15Average 145.2 Average | 4.76%Poor 4.76% Poor | 9.99%Poor 9.99% Poor | 0.51Good 0.5 Good | 41.72%Excellent 41.72% Excellent | 26.38%Excellent 26.38% Excellent | 0.00% |
Rainbow Childrens Medicare Pvt LtdRainbow Childre... RAINBOW • 543524 | 54.6/100 | ₹1377.10₹1377 | ₹13410.38₹13410.38 | 52.84Average 52.8 Average | 17.43%Good 17.43% Good | 18.69%Good 18.69% Good | 0.54Good 0.5 Good | 33.66%Excellent 33.66% Excellent | 16.08%Excellent 16.08% Excellent | 0.23% |
62.9/100 | ₹1326.10₹1326 | ₹9678.17₹9678.17 | 48.76Average 48.8 Average | 14.95%Average 14.95% Average | 17.95%Good 17.95% Good | 0.28Excellent 0.3 Excellent | 43.62%Excellent 43.62% Excellent | 22.20%Excellent 22.20% Excellent | 0.07% | |
Top Hospital Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Max Healthcare Institute Ltd share price109416.28 Cr
- Apollo Hospitals Enterprise Ltd share price104825.94 Cr
- Fortis Healthcare Ltd share price68301.24 Cr
- Narayana Hrudayalaya Ltd share price39051.19 Cr
- Aster DM Healthcare Ltd share price34688.15 Cr
Healthcare Global Enterprises Ltd PE Ratio History
Historical price-to-earnings ratio for HCG — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹3.14 | ₹662.00 | 210.8x |
| FY 2024 | ₹3.43 | ₹489.15 | 142.6x |
| FY 2023 | ₹2.10 | ₹365.50 | 174x |
| FY 2022 | ₹3.97 | ₹287.45 | 72.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Healthcare Global Enterprises Ltd Quarterly Performance
Latest quarterly metrics for HCG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.86%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-9.56%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.22%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
19.34%
Compounded annual net profit growth over 5 years
Healthcare Global Enterprises Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HCG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Healthcare Global Enterprises Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Healthcare Global Enterprises Ltd (HCG) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Healthcare Global Enterprises Ltd
About HCG (Healthcare Global Enterprises Ltd)
Healthcare Global Enterprises Ltd is a leading institution redefining cancer care within its hospital settings. Stepping inside, one encounters a meticulously designed environment,... intended to foster healing and well-being. The advanced infrastructure houses cutting-edge diagnostic and treatment technologies, from high-resolution imaging suites to specialized operating theaters equipped for complex oncological procedures. A palpable sense of hope permeates the air, amplified by the presence of compassionate medical staff who prioritize patient comfort and understanding. The hospital's architecture emphasizes natural light and open spaces, aiming to minimize anxiety and create a welcoming atmosphere for patients and their families navigating challenging circumstances. Art installations and calming color palettes further contribute to a holistic approach that extends beyond mere physical treatment. Beyond the physical infrastructure, HCG hospitals are hubs of medical innovation and expertise. A multidisciplinary team of oncologists, surgeons, radiologists, and support staff collaborate seamlessly to deliver personalized treatment plans tailored to each patient's unique needs. Research and development are integral components of the hospital's ethos, driving the adoption of novel therapies and techniques. Regular training programs ensure that healthcare professionals stay at the forefront of oncological advancements. Emphasis is placed on precision medicine, utilizing advanced genomic testing and molecular diagnostics to optimize treatment effectiveness while minimizing side effects. This commitment to pioneering approaches positions HCG as a center of excellence in cancer care. The patient experience at HCG hospitals extends far beyond the confines of medical procedures. A comprehensive support system is in place to address the emotional, psychological, and social needs of individuals undergoing cancer treatment. Counseling services, support groups, and palliative care are readily available, fostering a sense of community and shared understanding. The hospital emphasizes open communication and patient empowerment, ensuring that individuals are actively involved in their care decisions. Furthermore, nutritional guidance, rehabilitation programs, and survivorship support are integrated into the treatment journey, promoting long-term well-being and improving the quality of life for patients and their families.
Company Details
Key Leadership
HCG Share Price: Frequently Asked Questions
What is the current share price of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd (HCG) trades at ₹631.65 on NSE and BSE. Market cap ₹10.47K (Cr). Educational data only.
What is the P/E ratio of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has a P/E of 296.22x vs industry average 52.84x.
What is the Bull Run score for Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has a Bull Run score of 36.4/100 based on 25+ financial parameters.
Does Healthcare Global Enterprises Ltd pay dividends?
Healthcare Global Enterprises Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has ROE of 5.14%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Healthcare Global Enterprises Ltd?
Healthcare Global Enterprises Ltd has debt-to-equity of 1.92.
Is Healthcare Global Enterprises Ltd a good investment?
Bull Run gives Healthcare Global Enterprises Ltd a score of 36.4/100. This is not investment advice — consult a SEBI-registered advisor.